TrialArthritis research & therapy2024

A phase 3, randomized, double-blind, active-controlled clinical trial to compare BAT1806/BIIB800, a tocilizumab biosimilar, with tocilizumab reference product in participants with moderate-to-severe rheumatoid arthritis with inadequate response to methotrexate: treatment period 2 analysis (week 24 to week 48).

Xiaomei Leng et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.